Thrombopoietin Receptor Agonists Are Often Ineffective in Immune Thrombocytopenia and/or Cause Adverse Reactions: Results from One Hand | Zendy

Fabian Depré | Zendy; Nasra Aboud | Zendy; Frauke Ringel | Zendy; Abdulgabar Salama | Zendy

Open Access

Thrombopoietin Receptor Agonists Are Often Ineffective in Immune Thrombocytopenia and/or Cause Adverse Reactions: Results from One Hand

Author(s) -

Fabian Depré,

Nasra Aboud,

Frauke Ringel,

Abdulgabar Salama

Publication year - 2016

Publication title -

transfusion medicine and hemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.971

H-Index - 39

eISSN - 1660-3818

pISSN - 1660-3796

DOI - 10.1159/000446195

Subject(s) - eltrombopag , romiplostim , thrombopoietin receptor , adverse effect , medicine , thrombopoietin , immune thrombocytopenia , platelet , genetics , stem cell , haematopoiesis , biology

Eltrombopag and romiplostim are thrombopoietin receptor agonists (TPOs) that have been increasingly used for the treatment of immune thrombocytopenia (ITP). Based on our experience, the incidence of abortive treatment with these drugs and the occurrence of adverse reactions that lead to therapy break-off despite response are higher than has been previously suggested.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research